Concerns about Ozempic and reported suicidal thoughts are being probed by an EU regulator

A European Union regulator will hold a follow-up meeting this week as it reviews anecdotal reports of users of popular diabetes and weight loss drugs — including Novo Nordisk’s Ozempic — saying they experienced suicidal thoughts after starting the medications. The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee will discuss the probe this week, a meeting agenda revealed on Monday. The medications to be discussed include Novo Nordisk’s Ozempic, Saxenda, and Wegovy, as well as Eli Lilly’s Trulicity. These are all members of popular a class of drugs known...